HK1164153A1 - Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38 - Google Patents

Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38

Info

Publication number
HK1164153A1
HK1164153A1 HK12105112.8A HK12105112A HK1164153A1 HK 1164153 A1 HK1164153 A1 HK 1164153A1 HK 12105112 A HK12105112 A HK 12105112A HK 1164153 A1 HK1164153 A1 HK 1164153A1
Authority
HK
Hong Kong
Prior art keywords
vincristine
containing antibodies
antibodies recognizing
combinations containing
recognizing specifically
Prior art date
Application number
HK12105112.8A
Other languages
English (en)
Chinese (zh)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1164153A1 publication Critical patent/HK1164153A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK12105112.8A 2008-11-28 2012-05-24 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38 HK1164153A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291117A EP2191841A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
PCT/IB2009/055390 WO2010061358A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine

Publications (1)

Publication Number Publication Date
HK1164153A1 true HK1164153A1 (en) 2012-09-21

Family

ID=40627439

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105112.8A HK1164153A1 (en) 2008-11-28 2012-05-24 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38

Country Status (31)

Country Link
US (1) US8633301B2 (pt)
EP (2) EP2191841A1 (pt)
JP (2) JP2012510462A (pt)
KR (1) KR101733253B1 (pt)
CN (1) CN102264388B (pt)
AR (1) AR074220A1 (pt)
AU (1) AU2009321250B2 (pt)
BR (1) BRPI0922304B1 (pt)
CA (1) CA2744996C (pt)
CL (1) CL2011001255A1 (pt)
CO (1) CO6361946A2 (pt)
CR (1) CR20110281A (pt)
DO (1) DOP2011000118A (pt)
EA (1) EA026092B1 (pt)
EC (1) ECSP11011064A (pt)
HK (1) HK1164153A1 (pt)
HN (1) HN2011001420A (pt)
IL (1) IL213117A (pt)
MA (1) MA32895B1 (pt)
MX (1) MX2011005539A (pt)
NI (1) NI201100106A (pt)
NZ (1) NZ592992A (pt)
PA (1) PA8850001A1 (pt)
PE (1) PE20110821A1 (pt)
SG (1) SG171822A1 (pt)
TN (1) TN2011000163A1 (pt)
TW (1) TWI457124B (pt)
UA (1) UA105507C2 (pt)
UY (1) UY32265A (pt)
WO (1) WO2010061358A1 (pt)
ZA (1) ZA201103923B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
BR112013006769B1 (pt) 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
LT2900232T (lt) 2012-09-25 2018-02-26 Morphosys Ag Deriniai ir jų panaudojimas
TW201522378A (zh) 2013-10-31 2015-06-16 Sanofi Sa 用於治療人類癌症的特異性抗cd38抗體
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US20170212130A1 (en) * 2014-06-25 2017-07-27 The Rockefeller University Compositions and methods for rapid production of versatile nanobody repertoires
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
NZ738406A (en) * 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA43187B1 (fr) 2015-11-03 2021-02-26 Janssen Biotech Inc Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN113574071A (zh) 2019-03-15 2021-10-29 莫佛塞斯公司 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) 2019-11-29 2022-08-16 康诺亚生物医药科技(成都)有限公司 药物组合物及其制备方法和应用
CN115698064A (zh) 2019-12-05 2023-02-03 赛诺菲-安万特美国有限责任公司 用于皮下施用的抗cd38抗体的配制品
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗cd38抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999062526A2 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
ES2541489T3 (es) 2004-02-06 2015-07-21 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
CN101218256B (zh) * 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US9040050B2 (en) * 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
US20080092384A1 (en) * 2006-10-16 2008-04-24 Schaake Mark D Installation of Middle Bearing for a Crankshaft
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
CN102264388B (zh) 2014-07-16
ZA201103923B (en) 2012-09-26
MA32895B1 (fr) 2011-12-01
HN2011001420A (es) 2014-01-13
UA105507C2 (uk) 2014-05-26
NZ592992A (en) 2012-12-21
JP2012510462A (ja) 2012-05-10
CL2011001255A1 (es) 2012-01-27
IL213117A0 (en) 2011-07-31
PE20110821A1 (es) 2011-11-19
AR074220A1 (es) 2010-12-29
TW201024310A (en) 2010-07-01
CN102264388A (zh) 2011-11-30
EA201100867A1 (ru) 2011-10-31
CA2744996C (en) 2019-05-07
BRPI0922304A2 (pt) 2016-06-21
AU2009321250B2 (en) 2016-05-26
MX2011005539A (es) 2011-10-10
CA2744996A1 (en) 2010-06-03
CR20110281A (es) 2011-12-07
BRPI0922304B1 (pt) 2022-08-09
IL213117A (en) 2017-08-31
JP6130871B2 (ja) 2017-05-17
KR101733253B1 (ko) 2017-05-08
UY32265A (es) 2010-06-30
US8633301B2 (en) 2014-01-21
SG171822A1 (en) 2011-07-28
US20110293606A1 (en) 2011-12-01
NI201100106A (es) 2011-09-26
TWI457124B (zh) 2014-10-21
AU2009321250A1 (en) 2010-06-03
TN2011000163A1 (en) 2012-12-17
EP2370095B1 (en) 2020-04-01
EA026092B1 (ru) 2017-03-31
PA8850001A1 (es) 2010-07-27
DOP2011000118A (es) 2011-06-30
WO2010061358A1 (en) 2010-06-03
CO6361946A2 (es) 2012-01-20
ECSP11011064A (es) 2011-07-29
EP2191841A1 (en) 2010-06-02
JP2015172049A (ja) 2015-10-01
KR20110091785A (ko) 2011-08-12
EP2370095A1 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
HK1164153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38
IL213118A0 (en) Antitumor combinations containing antibodies recognizing specifically cd38 andcyclophosphamide
HRP20181787T1 (hr) Antitumorske kombinacije koje sadržavaju protutijela koja specifično prepoznaju cd38 i bortezomib
HK1164154A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38
HK1164165A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan cd38
EP2507397A4 (en) CLASSIFICATION OF CANCERS
HK1166247A1 (en) Luggage
EP2408814A4 (en) CARRIER IMMUNOGLOBULINE AND USES THEREOF
IL218108A (en) Anti-il1rap antibody for use in the treatment of leukemia
HRP20150133T1 (hr) Instant napitak na bazi žitarica
GB201112947D0 (en) Relative permeability modification
EP2303642A4 (en) ROOF RACK
EP2240271A4 (en) SEPARATION OF BIOMOLECULES
GB201001080D0 (en) Self-Weighing luggage
GB0915191D0 (en) Decorative Cover
GB0813577D0 (en) Abs station
GB0807491D0 (en) Particles
PL118559U1 (pl) Nośnik ozdób
PL386793A1 (pl) Konik obrabiarki
PL386792A1 (pl) Konik obrabiarki

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171127